Search results
Results from the WOW.Com Content Network
Teplizumab. Teplizumab, sold under the brand name Tzield, is a humanized anti-CD3 monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D. [3][4][5] The Fc region of this antibody has been engineered to have Fc receptor non-binding (FNB) properties. [6]
Semaglutide is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. [ 19 ] [ 20 ] [ 21 ] It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain .
Tirzepatide is an antidiabetic medication used for the treatment of type 2 diabetes [10][13][14][15] and for weight loss. [11][16] Tirzepatide is administered via subcutaneous injections (under the skin). [10][13] It is sold under the brand names Mounjaro for diabetes treatment, [10] and Zepbound for weight loss. [11]
Juvenile Diabetes Research Foundation. Breakthrough T1D is a nonprofit 501 (c) (3) organization that funds type 1 diabetes (T1D) research, provides a broad array of community and activist services to the T1D population and actively advocates for regulation favorable to medical research and approval of new and improved treatment modalities. It ...
Canadian endocrinologist Daniel J. Drucker — a diabetes treatment pioneer whose work paved the way for Ozempic — is sharing what’s next for this class of obesity-fighting drugs, which mimic ...
Liraglutide, sold under the brand names Victoza and Saxenda among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. [6] [7] It is a second-line therapy for diabetes following first-line therapy with metformin. [6] [8] Its effects on long-term health outcomes like heart disease and life expectancy are ...
SGLT2 inhibitors lowered dementia, Parkinson’s risk by 22%. For this study, the researchers accessed data from 358,862 participants with type 2 diabetes and followed them for an average of 9.6 ...
Insulin glargine/lixisenatide is approved as a prescription for adults with type 2 diabetes mellitus poorly controlled by lixisenatide or basal insulin alone. [6] According to the American Diabetes Association, combination treatment of a GLP-1 receptor agonist with basal insulin should occur after HbA1C levels remain above target (7% for most type 2 people with diabetes) following use of basal ...